Your supposition is not wrong with regard to AAIC; however, I believe, as in the past, Anavex will continue to compare its results against historical placebo data from past Alz trials, which have be developed over decades of time and is a good comparative measure in assessing the potential of a drug candidate. Only the naysayers will dismiss any reports of good data.
Market Data 
Markets 
